{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:00:58Z","timestamp":1791576058153,"version":"4.3.4"},"reference-count":11,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2022,5,11]]},"DOI":"10.18632\/oncotarget.28229","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T12:36:18Z","timestamp":1652272578000},"page":"677-683","source":"Crossref","is-referenced-by-count":17,"title":["Tazemetostat in relapsed\/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes"],"prefix":"10.18632","volume":"13","author":[{"given":"David G.","family":"Proudman","sequence":"first","affiliation":[{"name":"Analysis Group, Inc., Menlo Park, CA 94025, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepshekhar","family":"Gupta","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Menlo Park, CA 94025, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Nellesen","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Menlo Park, CA 94025, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Yang","sequence":"additional","affiliation":[{"name":"Epizyme, Inc., Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Kamp","sequence":"additional","affiliation":[{"name":"Epizyme, Inc., Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Mamlouk","sequence":"additional","affiliation":[{"name":"Epizyme, Inc., Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[{"name":"Lymphoma Research Foundation, New York, NY 10005, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"1","unstructured":"National Cancer Institute. Adult non-Hodgkin lymphoma treatment (PDQ\u00ae)-health professional version. https:\/\/www.cancer.gov\/types\/lymphoma\/hp\/adult-nhl-treatment-pdq#_1."},{"key":"2","unstructured":"Surveillance Epidemiology and End Results Program. SEER cancer stat facts: NHL - follicular lymphoma. https:\/\/seer.cancer.gov\/statfacts\/html\/follicular.html."},{"key":"3","unstructured":"Tazverik. Epizyme, Inc.; 2000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213400s000lbl.pdf."},{"key":"4","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"2","author":"Kazmierczak","year":"2020","journal-title":"Lancet Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"e190972","DOI":"10.1001\/jamasurg.2019.0972","article-title":"Effect of Vein-First vs Artery-First Surgical Technique on Circulating Tumor Cells and Survival in Patients With Non-Small Cell Lung Cancer: A Randomized Clinical Trial and Registry-Based Propensity Score Matching Analysis","volume":"15","author":"Liao","year":"2019","journal-title":"JAMA Surg"},{"key":"6","doi-asserted-by":"publisher","first-page":"100321","DOI":"10.1016\/j.esxm.2021.100321","article-title":"Treatment Patterns and Healthcare Outcomes with Collagenase Clostridium Histolyticum vs Surgery in Peyronie\u2019s Disease: A Retrospective Claims Database Analysis","volume":"9","author":"Hu","year":"2021","journal-title":"Sex Med"},{"key":"7","doi-asserted-by":"publisher","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"11","author":"Arber","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nri3814","article-title":"Germinal centres and B cell lymphomagenesis","volume":"1","author":"Dalla-Favera","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"9","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/nm.3940","article-title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis","volume":"2","author":"Pasqualucci","year":"2015","journal-title":"Nat Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Murty","year":"2014","journal-title":"Cell Rep"},{"key":"11","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1038\/bcj.2017.32","article-title":"EZH2 alterations in follicular lymphoma: biological and clinical correlations","volume":"7","author":"Hayette","year":"2017","journal-title":"Blood Cancer J"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T12:36:22Z","timestamp":1652272582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,5,11]]}},"alternative-id":["28229"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28229","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]}}}